1. World Health Organization WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int/. Accessed 18 Jul 2021
2. Elezkurtaj S, Greuel S, Ihlow J, et al (2021) Causes of death and comorbidities in hospitalized patients with COVID-19. Scientific Reports 11:. https://doi.org/10.1038/s41598-021-82862-5
3. Ma L, Song K, Huang Y (2021) Coronavirus Disease-2019 (COVID-19) and Cardiovascular Complications. Journal of Cardiothoracic and Vascular Anesthesia 35:. https://doi.org/10.1053/j.jvca.2020.04.041
4. Guo T, Fan Y, Chen M, et al (2020) Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiology 5:. https://doi.org/10.1001/jamacardio.2020.1017
5. Zhou F, Yu T, Du R, et al (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet 395:1054–1062. https://doi.org/10.1016/S0140-6736(20)30566-3
6. Que Y, Hu C, Wan K, et al (2021) Cytokine release syndrome in COVID-19: a major mechanism of morbidity and mortality. International Reviews of Immunology
7. Wenjun W, Xiaoqing L, Sipei W, et al (2020) The definition and risks of cytokine release syndrome-like in 11 COVID-19-infected pneumonia critically ill patients: Disease characteristics and retrospective analysis. medRxiv. https://doi.org/10.1101/2020.02.26.20026989
8. Inciardi RM, Adamo M, Lupi L, et al (2020) Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy. European Heart Journal 41:. https://doi.org/10.1093/eurheartj/ehaa388
9. Mehra MR, Desai SS, Kuy S, et al (2020) Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. New England Journal of Medicine 382:. https://doi.org/10.1056/NEJMoa2007621
10. Saleh K bin, Hafiz A, Alsulaiman K, et al (2021) Clinical characteristics and outcomes of patients with heart failure admitted to the intensive care unit with coronavirus disease 2019 (COVID-19): A multicenter cohort study. American Heart Journal Plus: Cardiology Research and Practice 7:. https://doi.org/10.1016/j.ahjo.2021.100033
11. Chou R, Dana T, Blazina I, et al (2016) Statins for Prevention of Cardiovascular Disease in Adults. JAMA 316:. https://doi.org/10.1001/jama.2015.15629
12. Mach F, Baigent C, Catapano AL, et al (2020) 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal 41:. https://doi.org/10.1093/eurheartj/ehz455
13. Grundy SM, Stone NJ, Bailey AL, et al (2019) 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 139:. https://doi.org/10.1161/CIR.0000000000000624
14. Arnett DK, Blumenthal RS, Albert MA, et al (2019) 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 140:. https://doi.org/10.1161/CIR.0000000000000678
15. Oesterle A, Laufs U, Liao JK (2017) Pleiotropic Effects of Statins on the Cardiovascular System. Circulation Research 120:. https://doi.org/10.1161/CIRCRESAHA.116.308537
16. Bikdeli B, Madhavan M v., Gupta A, et al (2020) Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. Thrombosis and Haemostasis 120:. https://doi.org/10.1055/s-0040-1713152
17. Lee KCH, Sewa DW, Phua GC (2020) Potential role of statins in COVID-19. International Journal of Infectious Diseases 96:. https://doi.org/10.1016/j.ijid.2020.05.115
18. Gorabi AM, Kiaie N, Bianconi V, et al (2020) Antiviral effects of statins. Progress in Lipid Research 79:. https://doi.org/10.1016/j.plipres.2020.101054
19. Cariou B, Goronflot T, Rimbert A, et al (2021) Routine use of statins and increased COVID-19 related mortality in inpatients with type 2 diabetes: Results from the CORONADO study. Diabetes & Metabolism 47:. https://doi.org/10.1016/j.diabet.2020.10.001
20. Zhang X-J, Qin J-J, Cheng X, et al (2020) In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19. Cell Metabolism 32:. https://doi.org/10.1016/j.cmet.2020.06.015
21. Kow CS, Hasan SS (2020) Meta-analysis of Effect of Statins in Patients with COVID-19. The American Journal of Cardiology 134:. https://doi.org/10.1016/j.amjcard.2020.08.004
22. Hariyanto TI, Kurniawan A (2020) Statin therapy did not improve the in-hospital outcome of coronavirus disease 2019 (COVID-19) infection. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 14:. https://doi.org/10.1016/j.dsx.2020.08.023
23. Bikdeli B, Talasaz AH, Rashidi F, et al (2020) Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies. Thrombosis Research 196:. https://doi.org/10.1016/j.thromres.2020.09.027
24. Lin C-Y (2012) Acute kidney injury classification: AKIN and RIFLE criteria in critical patients. World Journal of Critical Care Medicine 1:40. https://doi.org/10.5492/wjccm.v1.i2.40
25. American Thoracic Society Documents (2005) Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia. American Journal of Respiratory and Critical Care Medicine 171:. https://doi.org/10.1164/rccm.200405-644ST
26. Aleidan FAS, Alkhelaifi H, Alsenaid A, et al (2021) Incidence and risk factors of carbapenem-resistant Enterobacteriaceae infection in intensive care units: a matched case–control study. Expert Review of Anti-infective Therapy 19:393–398. https://doi.org/10.1080/14787210.2020.1822736
27. Koenig SM, Truwit JD (2006) Ventilator-Associated Pneumonia: Diagnosis, Treatment, and Prevention. Clinical Microbiology Reviews 19:. https://doi.org/10.1128/CMR.00051-05
28. Davignon J (2004) Beneficial Cardiovascular Pleiotropic Effects of Statins. Circulation 109:. https://doi.org/10.1161/01.CIR.0000131517.20177.5a
29. Scheen AJ (2021) Statins and clinical outcomes with COVID-19: Meta-analyses of observational studies. Diabetes & Metabolism 47:. https://doi.org/10.1016/j.diabet.2020.101220
30. Russo V, Silverio A, Scudiero F, et al (2021) Preadmission Statin Therapy and Clinical Outcome in Hospitalized Patients With COVID-19: An Italian Multicenter Observational Study. Journal of Cardiovascular Pharmacology 78:. https://doi.org/10.1097/FJC.0000000000001041
31. Bavry Anthony A. (2021) Intermediate Versus Standard-Dose Prophylactic Anticoagulation in Critically Ill Patients With COVID-19 - INSPIRATION-S. https://www.acc.org/latest-in-cardiology/clinical-trials/2021/05/14/03/14/inspiration-s. Accessed 1 Aug 2021
32. Song SL, Hays SB, Panton CE, et al (2020) Statin Use Is Associated with Decreased Risk of Invasive Mechanical Ventilation in COVID-19 Patients: A Preliminary Study. Pathogens 9:. https://doi.org/10.3390/pathogens9090759
33. Guan W, Ni Z, Hu Y, et al (2020) Clinical Characteristics of Coronavirus Disease 2019 in China. New England Journal of Medicine 382:1708–1720. https://doi.org/10.1056/nejmoa2002032
34. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1999;100(3):230-235. doi:10.1161/01.cir.100.3.230
35. Charo IF, Taub R. Anti-inflammatory therapeutics for the treatment of atherosclerosis. Nat Rev Drug Discov. 2011;10(5):365-376. doi:10.1038/nrd3444
36. Masadeh M, Mhaidat N, Alzoubi K, Al-Azzam S, Alnasser Z. Antibacterial activity of statins: a comparative study of atorvastatin, simvastatin, and rosuvastatin. Ann Clin Microbiol Antimicrob. 2012;11:13. Published 2012 May 7. doi:10.1186/1476-0711-11-13
37. Ko HHT, Lareu RR, Dix BR, Hughes JD. Statins: antimicrobial resistance breakers or makers?. PeerJ. 2017;5:e3952. Published 2017 Oct 24. doi:10.7717/peerj.3952
38. S. Jerwood, J. Cohen, Unexpected antimicrobial effect of statins, Journal of Antimicrobial Chemotherapy, Volume 61, Issue 2, February 2008, Pages 362–364, https://doi.org/10.1093/jac/dkm496